Adjuvant Trastuzumab for HER-2 Positive Early Breast Cancer
Author Information
Author(s): Viani Gustavo A, Afonso Sergio L, Stefano Eduardo J, De Fendi Ligia I, Soares Francisco V
Primary Institution: Faculdade de Medicina de Marília (FAMEMA), Marília, São Paulo, Brazil
Hypothesis
Is adjuvant trastuzumab effective in reducing mortality, recurrence, and metastases in HER-2 positive early breast cancer?
Conclusion
Adjuvant trastuzumab significantly reduces mortality and recurrence rates in women with HER-2 positive early breast cancer, but it is associated with increased cardiac toxicity.
Supporting Evidence
- Pooled results from five randomized trials showed a significant reduction in mortality and recurrence rates with trastuzumab.
- Cardiac toxicity was higher in patients receiving trastuzumab compared to those who did not.
- The likelihood of brain metastases was found to be higher in patients treated with trastuzumab.
Takeaway
This study shows that giving a medicine called trastuzumab to women with a certain type of breast cancer helps them live longer and have fewer cancer returns, but it can also cause heart problems.
Methodology
A meta-analysis of randomized controlled trials comparing adjuvant trastuzumab treatment for HER2-positive early breast cancer to observation.
Potential Biases
Potential publication bias due to the tendency of journals to favor positive studies.
Limitations
The study relied on published data rather than individual patient data, which may overestimate treatment effects.
Participant Demographics
Patients with HER-2 positive invasive breast cancer, both node positive and high-risk node-negative.
Statistical Information
P-Value
<0.00001
Confidence Interval
95% CI 1.89 – 3.16
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website